INS and Hypoglycemia: As hypoglycaemia is one of the main considerations in evaluating the safety of pharmaceuticals which potentiate insulin secretion, and GLP-1RA are considered low risk for hypoglycaemia due to their glucose-dependent insulinotropic action (119), activation of GLP-1R in substimulatory glucose seems contradictory.